Fulcrum director granted 32,000 stock options
Fulcrum Therapeutics, Inc. director James A. Geraghty received a grant of stock options covering 32,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Fulcrum Therapeutics, Inc. director James A. Geraghty received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $3.66 per share and expire on June 29, 2036. According to the grant terms, all 32,000 options are scheduled to vest on the first anniversary of the June 30, 2026 grant date, or earlier immediately before the first annual stockholder meeting after that date, subject to his continued service.
Insider Trade Summary
Grant/Award: 32,000 shares
Grant/Award
1 txn
Insider
GERAGHTY JAMES A
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 32,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 32,000 contracts (Direct)
Footnotes (1)
- F1. This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
Key Figures
Options granted: 32,000 options
Exercise price: $3.66 per share
Underlying shares: 32,000 shares
+3 more
6 metrics
Options granted
32,000 options
Stock Option (right to buy) grant to director
Exercise price
$3.66 per share
Exercise price for the granted stock options
Underlying shares
32,000 shares
Common stock underlying the option grant
Total derivative holdings after grant
32,000 options
Total options held following this transaction
Grant date
June 30, 2026
Date the stock option grant was awarded
Expiration date
June 29, 2036
Option expiration for this grant
Key Terms
Stock Option (right to buy), exercise price, Common Stock, grant date, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "3.6600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
grant date financial
"This option was granted on June 30, 2026 and is scheduled to vest..."
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
vest financial
"and is scheduled to vest with respect to all shares on the first anniversary..."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Fulcrum Therapeutics (FULC) report for James A. Geraghty?
Fulcrum Therapeutics reported that director James A. Geraghty received a stock option grant for 32,000 shares. The options relate to common stock and were awarded as compensation, rather than being purchased in the open market, and represent a routine director equity grant.
What is the exercise price of the new Fulcrum Therapeutics (FULC) stock options?
The granted stock options have an exercise price of $3.66 per share. This means Geraghty can buy Fulcrum Therapeutics common stock at $3.66 once the options vest, if he chooses to exercise them during the option term before expiration.
When do James A. Geraghty’s Fulcrum Therapeutics (FULC) options vest?
The 32,000 stock options are scheduled to vest in full on the first anniversary of the June 30, 2026 grant date. They may vest earlier, immediately before the first annual stockholder meeting after the grant date, provided he continues in service until that time.
When do the newly granted Fulcrum Therapeutics (FULC) stock options expire?
The stock options granted to James A. Geraghty expire on June 29, 2036. After that expiration date, any unexercised options become worthless, so exercise would need to occur between vesting and this expiration under the plan’s terms.
How many Fulcrum Therapeutics (FULC) derivative securities does James A. Geraghty hold after this Form 4?
Following the grant, Geraghty holds 32,000 stock options directly as reported in the filing. These options each relate to one share of common stock, giving him the right to buy up to 32,000 shares if he exercises them after vesting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates